Tag Archives: Donepezil

Pharmacological Treatment of Dementia

General guidelines for psychotropic medication use in frail elderly patients are applicable. Systematic evidence to support the effectiveness of particular psychotropic drugs in dementia patients is limited. Therefore, choice of drug class may be based on clinical evidence, and choice of agent is often based on the side-effect profile and on the characteristics of a… Read More »

Alzheimer’s Disease Therapies

Current Therapies for Alzheimer’s Disease Because there is currently no cure for Alzheimer’s disease (), the primary goal of treatment remains the relief of cognitive, functional, and behavioral symptoms associated with the disease. Hence, current therapies aim to improve the quality of life for both Alzheimer’s disease patients and the caregivers who often must cope… Read More »

Alzheimer’s Therapy: Beta-Amyloid Aggregation Inhibitors

Overview. Drugs in development to inhibit beta-amyloid aggregation include Praecis Pharmaceuticals’ Apan (PPI-1019), a compound developed by Senexis in preclinical testing, and Hoffmann-La Roche’s CPHPC. PPI-1019 is in Phase I development and has been shown in animal models to increase Aβ-40 levels in the cerebrospinal fluid (CSF), suggesting that the drug promotes the clearance of… Read More »

Alzheimer’s Therapy: N-Methyl-D-Aspartate Receptor Antagonists

Overview. A consequence of Alzheimer’s disease is neuronal loss, the result of a cascade of complex intracellular events. Excitotoxic reactions due to excessive glutamate release are thought to contribute to this neuronal cell death. Blocking glutamate receptors (NMDA receptors) is one approach to reducing cell death. In the past, however, drugs targeting NMDA receptors have… Read More »

Alzheimer’s Therapy: Acetylcholinesterase Inhibitors

Overview. Acetylcholinesterase inhibitors are the only drugs approved for the treatment of mild to moderate Alzheimer’s disease in the major markets. acetylcholinesterase inhibitors do not cure Alzheimer’s disease but do alleviate the cholinergic deficit observed in Alzheimer’s disease patients. Cognitive symptoms are occasionally improved but most often are only stabilized by the drugs (). Studies… Read More »

Alzheimer’s Therapy: Galantamine

Galantamine (Shire/Janssen’s Razadyne) () is the most recent entrant in the Alzheimer’s disease market. Galantamine was approved for the treatment of mild to moderate Alzheimer’s disease in the United States and Europe in 2001. The agent is in Phase III clinical trials in Japan. Galantamine is currently in Phase III trials in the United States… Read More »

Nonstimulant medications in the treatment of adults with ADHD

Here are some important points regarding nonstimulants in the treatment of adults with ADHD. Tricyclic antidepressants and bupropion are second-line therapies. Antidepressant dosing of the agents appears necessary for attention deficit hyperactivity disorder efficacy. Serotonergic medications do not appear effective in the treatment of core attention deficit hyperactivity disorder symptoms but may be useful for… Read More »

Information about Alzheimer’s Disease for Patients and Families

Alzheimer’s disease is the most common and well-known form of degenerative dementia. By definition, dementia is a syndrome, a cluster of symptoms, of impaired memory and cognition. Dementia is a cognitive disorder that impairs an individual’s memory and ability for reasoning, awareness, and judgment. Cognitive impairment in Alzheimer’s disease may involve disturbance of language (aphasia),… Read More »